Tofersen not checked

Biogen · BIIB067

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 4 trial completes
Trials
2 active
5 in total · 1 in the EU
Targets
 

What this is

How it works
A short strand of genetic material that blocks one gene's message, so the body makes less of one protein.Antisense Oligonucleotide FDA class
Tested for
Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Main trialPhase 4
“In this study, researchers will learn more about the safety of tofersen, also known as Qalsody®. This is a drug available for doctors to prescribe for people with a certain type of amyotrophic lateral sclerosis, also known as ALS. This type is in people who have a mutation in the superoxide dismutase 1 gene, also known as SOD-1. This is known as a "postmarketing" study. In this kind of the study, the goal is to learn more about how a drug works after it has been approved for use in the general public. Tofersen was approved in China in September 2024. The main goal of this study is to collect…”In the company’s words, NCT07223723 on ClinicalTrials.gov
Other names
BIIB067 · QALSODY

Other drugs for Amyotrophic Lateral Sclerosis

All 48 drugs for Amyotrophic Lateral Sclerosis

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 4Active, not recruiting 26 May 2027 A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)
Phase 3Active, not recruiting 7 Aug 2027 Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms
Phase 3Completed 16 Jul 2021 An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)
Phase 3Completed 12 Aug 2024 Long-Term Evaluation of BIIB067 (Tofersen)
Phase 1Completed 10 Jun 2021 A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Tofersen

Following is part of Solo: you see every change to Tofersen the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in